Erratum for Rhee et al., “Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants”

ERRATUM

Volume 62, no. 9, e00280-18, 2018, https://doi.org/10.1128/AAC.00280-18. The Acknowledgments section was incomplete and should appear as shown below.

At the time the study was conducted, E.G.R., M.L.R., N.C., M.N., M.S.S., E.M., K.B., P.B., F.C.-G., P.J., Y.L., and J.R.B. were employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD), and they may own stock and/or stock options in the company. S.J.W. is an employee of Hammersmith Medicines Research Ltd., London, UK. Funding for this research was provided by MSD.

All authors are responsible for the work described in this paper. All authors were involved in at least one of the following: study conception and design of work or acquisition, analysis, or interpretation of data; and drafting the manuscript and/or revising/reviewing the manuscript for important intellectual content. All authors provided final approval of the version to be published. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Medical writing and/or editorial assistance was provided by Stephanie Doerner and Alanna Kennedy of The Lockwood Group, Stamford, CT, USA. This assistance was funded by MSD.